WASHINGTON — The Food and Drug Administration will have to explain to a court this week why it won’t shed more light on an internal decision to allow at least two Americans who contracted Ebola to take a drug that wasn’t yet approved.

It’s the latest salvo in a legal case that could have broader implications for the ongoing campaign to pass a federal “right-to-try” law, in which advocates are aiming to help dying patients get access to other drugs the FDA hasn’t yet approved.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy